Last reviewed · How we verify

Efgartigimod IV or Efgartigimod PH20 SC

argenx · Phase 2 active Biologic

Efgartigimod IV or Efgartigimod PH20 SC is a Monoclonal antibody Biologic drug developed by argenx. It is currently in Phase 2 development for Myasthenia Gravis.

Monoclonal antibody targeting muscle relaxant proteins

Monoclonal antibody targeting muscle relaxant proteins Used for Myasthenia Gravis.

At a glance

Generic nameEfgartigimod IV or Efgartigimod PH20 SC
Sponsorargenx
Drug classMonoclonal antibody
TargetMuSK and LRP4
ModalityBiologic
Therapeutic areaNeurology
PhasePhase 2

Mechanism of action

Efgartigimod is a human IgG1 antibody that targets and depletes muscle relaxant proteins, including muscle-specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4).

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Efgartigimod IV or Efgartigimod PH20 SC

What is Efgartigimod IV or Efgartigimod PH20 SC?

Efgartigimod IV or Efgartigimod PH20 SC is a Monoclonal antibody drug developed by argenx, indicated for Myasthenia Gravis.

How does Efgartigimod IV or Efgartigimod PH20 SC work?

Monoclonal antibody targeting muscle relaxant proteins

What is Efgartigimod IV or Efgartigimod PH20 SC used for?

Efgartigimod IV or Efgartigimod PH20 SC is indicated for Myasthenia Gravis.

Who makes Efgartigimod IV or Efgartigimod PH20 SC?

Efgartigimod IV or Efgartigimod PH20 SC is developed by argenx (see full argenx pipeline at /company/argenx).

What drug class is Efgartigimod IV or Efgartigimod PH20 SC in?

Efgartigimod IV or Efgartigimod PH20 SC belongs to the Monoclonal antibody class. See all Monoclonal antibody drugs at /class/monoclonal-antibody.

What development phase is Efgartigimod IV or Efgartigimod PH20 SC in?

Efgartigimod IV or Efgartigimod PH20 SC is in Phase 2.

What are the side effects of Efgartigimod IV or Efgartigimod PH20 SC?

Common side effects of Efgartigimod IV or Efgartigimod PH20 SC include Injection site reaction, Headache, Fatigue.

What does Efgartigimod IV or Efgartigimod PH20 SC target?

Efgartigimod IV or Efgartigimod PH20 SC targets MuSK and LRP4 and is a Monoclonal antibody.

Related